These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
334 related articles for article (PubMed ID: 21343937)
21. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. Kulasingam SL; Hughes JP; Kiviat NB; Mao C; Weiss NS; Kuypers JM; Koutsky LA JAMA; 2002 Oct; 288(14):1749-57. PubMed ID: 12365959 [TBL] [Abstract][Full Text] [Related]
22. Study protocol of the CHOiCE trial: a three-armed, randomized, controlled trial of home-based HPV self-sampling for non-participants in an organized cervical cancer screening program. Tranberg M; Bech BH; Blaakær J; Jensen JS; Svanholm H; Andersen B BMC Cancer; 2016 Nov; 16(1):835. PubMed ID: 27809810 [TBL] [Abstract][Full Text] [Related]
23. Outcomes of prior cervical cytology and HR-HPV testing in women subsequently diagnosed with CIN1, CIN2/3, and invasive cervical cancer: a 4-year routine clinical experience after implementation of systematic training and quality control programs. Zhao D; Zhang L; Xie F; Peng D; Wei J; Jiang L; Zhang S; Qi D BMC Cancer; 2020 Aug; 20(1):810. PubMed ID: 32847541 [TBL] [Abstract][Full Text] [Related]
24. [Health technology assessment report. Use of liquid-based cytology for cervical cancer precursors screening]. Ronco G; Confortini M; Maccallini V; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Giorgi Rossi P Epidemiol Prev; 2012; 36(5 Suppl 2):e1-e33. PubMed ID: 23139163 [TBL] [Abstract][Full Text] [Related]
25. High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening. Snijders PJ; Verhoef VM; Arbyn M; Ogilvie G; Minozzi S; Banzi R; van Kemenade FJ; Heideman DA; Meijer CJ Int J Cancer; 2013 May; 132(10):2223-36. PubMed ID: 22907569 [TBL] [Abstract][Full Text] [Related]
26. Cytology versus HPV testing for cervical cancer screening in the general population. Koliopoulos G; Nyaga VN; Santesso N; Bryant A; Martin-Hirsch PP; Mustafa RA; Schünemann H; Paraskevaidis E; Arbyn M Cochrane Database Syst Rev; 2017 Aug; 8(8):CD008587. PubMed ID: 28796882 [TBL] [Abstract][Full Text] [Related]
27. Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia. Canfell K; Saville M; Caruana M; Gebski V; Darlington-Brown J; Brotherton J; Heley S; Castle PE BMJ Open; 2018 Jan; 8(1):e016700. PubMed ID: 29374658 [TBL] [Abstract][Full Text] [Related]
28. Validation of a new HPV self-sampling device for cervical cancer screening: The Cervical and Self-Sample In Screening (CASSIS) study. El-Zein M; Bouten S; Louvanto K; Gilbert L; Gotlieb W; Hemmings R; Behr MA; Franco EL; Gynecol Oncol; 2018 Jun; 149(3):491-497. PubMed ID: 29678360 [TBL] [Abstract][Full Text] [Related]
29. Primary cervical cancer screening by self-sampling of human papillomavirus DNA in internal medicine outpatient clinics. Dannecker C; Siebert U; Thaler CJ; Kiermeir D; Hepp H; Hillemanns P Ann Oncol; 2004 Jun; 15(6):863-9. PubMed ID: 15151941 [TBL] [Abstract][Full Text] [Related]
30. Can human papillomavirus DNA testing of self-collected vaginal samples compare with physician-collected cervical samples and cytology for cervical cancer screening in developing countries? Bhatla N; Dar L; Patro AR; Kumar P; Kriplani A; Gulati A; Iyer VK; Mathur SR; Sreenivas V; Shah KV; Gravitt PE Cancer Epidemiol; 2009 Dec; 33(6):446-50. PubMed ID: 19931499 [TBL] [Abstract][Full Text] [Related]
31. Offering self-sampling to cervical screening non-attenders in primary care. Lim AW; Hollingworth A; Kalwij S; Curran G; Sasieni P J Med Screen; 2017 Mar; 24(1):43-49. PubMed ID: 27235844 [TBL] [Abstract][Full Text] [Related]
32. Randomised trial of HPV self-sampling among non-attenders in the Slovenian cervical screening programme ZORA: comparing three different screening approaches. Ivanus U; Jerman T; Fokter AR; Takac I; Prevodnik VK; Marcec M; Gajsek US; Pakiz M; Koren J; Celik SH; Kramberger KG; Klopcic U; Kavalar R; Zatler SS; Kuzmanov BG; Florjancic M; Nolde N; Novakovic S; Poljak M; Zakelj MP Radiol Oncol; 2018 Sep; 52(4):399-412. PubMed ID: 30216191 [TBL] [Abstract][Full Text] [Related]
33. Switch from cytology-based to human papillomavirus test-based cervical screening: implications for colposcopy. Porras C; Wentzensen N; Rodríguez AC; Morales J; Burk RD; Alfaro M; Hutchinson M; Herrero R; Hildesheim A; Sherman ME; Wacholder S; Solomon D; Schiffman M Int J Cancer; 2012 Apr; 130(8):1879-87. PubMed ID: 21607948 [TBL] [Abstract][Full Text] [Related]
34. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Ronco G; Giorgi-Rossi P; Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Ghiringhello B; Girlando S; Gillio-Tos A; De Marco L; Naldoni C; Pierotti P; Rizzolo R; Schincaglia P; Zorzi M; Zappa M; Segnan N; Cuzick J; Lancet Oncol; 2010 Mar; 11(3):249-57. PubMed ID: 20089449 [TBL] [Abstract][Full Text] [Related]
35. Benefits and potential harms of human papillomavirus (HPV)-based cervical cancer screening: A real-world comparison of HPV testing versus cytology. Thomsen LT; Kjaer SK; Munk C; Ørnskov D; Waldstrøm M Acta Obstet Gynecol Scand; 2021 Mar; 100(3):394-402. PubMed ID: 33566361 [TBL] [Abstract][Full Text] [Related]
36. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study. Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222 [TBL] [Abstract][Full Text] [Related]
37. Human papillomavirus test with cytology triage in organized screening for cervical cancer. Veijalainen O; Kares S; Kujala P; Tirkkonen M; Vuento R; Kholová I; Luukkaala T; Osuala V; Mäenpää J Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1220-1227. PubMed ID: 27591407 [TBL] [Abstract][Full Text] [Related]
38. [HPV-Hr detection by home self sampling in women not compliant with pap test for cervical cancer screening. Results of a pilot programme in Bouches-du-Rhône]. Piana L; Leandri FX; Le Retraite L; Heid P; Tamalet C; Sancho-Garnier H Bull Cancer; 2011 Jul; 98(7):723-31. PubMed ID: 21700548 [TBL] [Abstract][Full Text] [Related]
39. Acceptance of Self-Sampling Among Long-Term Cervical Screening Non-Attenders with HPV-Positive Results: Promising Opportunity for Specific Cancer Education. Andersson S; Belkić K; Mints M; Östensson E J Cancer Educ; 2021 Feb; 36(1):126-133. PubMed ID: 31522376 [TBL] [Abstract][Full Text] [Related]
40. Type-specific human papillomavirus DNA testing with the genotyping array: a comparison of cervical and vaginal sampling. Twu NF; Yen MS; Lau HY; Chen YJ; Yu BK; Lin CY Eur J Obstet Gynecol Reprod Biol; 2011 May; 156(1):96-100. PubMed ID: 21288625 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]